Search

Your search keyword '"PUDDU A."' showing total 37 results
Start Over Author "PUDDU A." Journal cardiology
37 results on '"PUDDU A."'

6. Gene-Based Therapy for Hypertension – Do Preclinical Data Suggest a Promising Future?

Author

Paolo Emilio Puddu, Eleonora Ferrari, Antonio Muscari, Giovanni M. Puddu, Eleonora Cravero, Puddu G.M., Cravero E., Ferrari E., Muscari A., and Puddu P.

Subjects
Male, SENSE, Genetic enhancement, Genetic Vectors, Bioinformatics, Sensitivity and Specificity, GENE VECTORS, Renin-Angiotensin System, Mice, Risk Factors, Rats, Inbred SHR, Sense (molecular biology), Animals, Humans, Medicine, Pharmacology (medical), RNA, Small Interfering, Gene, GENE THERAPHY, business.industry, Gene Transfer Techniques, Genetic Therapy, Oligonucleotides, Antisense, Preclinical data, Virology, Rats, Disease Models, Animal, Blood pressure, Hypertension, Female, Cardiology and Cardiovascular Medicine, business, ANTISENSE, Forecasting
Abstract

Many experimental studies have obtained a prolonged control of blood pressure through gene treatment. This consists in the administration of genes coding for vasodilator proteins (the ‘sense’ approach), or of nucleotide sequences that are complementary to the mRNA of vasoconstrictor proteins, which are consequently synthesized in smaller amounts (the ‘antisense’ approach). Examples of the sense approach include the genes encoding endothelial nitric oxide synthase and kallikrein. Examples of the second type of approach are the antisense oligodeoxynucleotides to angiotensin-converting enzyme and endothelin-1. Also, RNA molecules, such as ribozymes and small interfering RNAs, are capable to inhibit RNA function. Whole sense genes are usually administered through viral vectors, while antisense oligonucleotides may be administered with plasmids or liposomes. Both viral and non-viral vectors have advantages and disadvantages. Despite the still persisting limitations, the possibility exists that in the future some forms of genetic treatment will be extended to the clinical setting, allowing a prolonged control of essential hypertension and its end-organ sequelae.

Published
2006

7. Mitochondrial dysfunction as an initiating event in atherogenesis: a plausible hypothesis

Author

Giovanni M. Puddu, Paolo Emilio Puddu, Eleonora Cravero, Antonio Muscari, Livia Galletti, Puddu P., Puddu G.M., Cravero E., and Muscari A.

Subjects
Mitochondrial DNA, medicine.medical_specialty, Programmed cell death, Endothelium, Arteriosclerosis, Mitochondrion, DNA, Mitochondrial, Internal medicine, Medicine, Animals, Humans, Pharmacology (medical), Endothelial dysfunction, chemistry.chemical_classification, Reactive oxygen species, Cell Death, business.industry, medicine.disease, Mitochondria, Lipoproteins, LDL, Oxidative Stress, medicine.anatomical_structure, Mitochondrial respiratory chain, Endocrinology, chemistry, Endothelium, Vascular, Cardiology and Cardiovascular Medicine, business, Lipoproteins, HDL, Reactive Oxygen Species, Lipoprotein, DNA Damage
Abstract

It is now widely accepted that oxidant stress and the ensuing endothelial dysfunction play a key role in the pathogenesis of atherosclerosis and cardiovascular diseases. The mitochondrial respiratory chain is the major source of reactive oxygen species as byproducts of normal cell respiration. Mitochondria may also be important targets for reactive oxygen species, which may damage mitochondrial lipids, enzymes and DNA with following mitochondrial dysfunction. Free cholesterol, oxidized low-density lipoprotein and glycated high-density lipoprotein are further possible causes of mitochondrial dysfunction and/or apoptosis. Moreover, in patients with mitochondrial diseases, vascular complications are commonly observed at an early age, often in the absence of traditional risk factors for atherosclerosis. We propose that mitochondrial dysfunction, besides endothelial dysfunction, represents an important early step in the chain of events leading to atherosclerotic disease.

Published
2004

8. Lipid-Lowering Drugs: Are Adverse Effects Predictable and Reversible?

Author

Antonio Muscari, Paolo Emilio Puddu, and Giovanni M. Puddu

Subjects
medicine.medical_specialty, Combination therapy, medicine.medical_treatment, Pharmacology, Rhabdomyolysis, Cytochrome P-450 Enzyme System, Internal medicine, medicine, Humans, Pharmacology (medical), Renal Insufficiency, Adverse effect, Hypolipidemic Agents, Acid derivative, Chemotherapy, business.industry, Cholesterol, LDL, Carbon-Carbon Lyases, Endocrinology, Liver, Steroid 16-alpha-Hydroxylase, Steroid Hydroxylases, Drug Therapy, Combination, Aryl Hydrocarbon Hydroxylases, Lipid lowering, Bezafibrate, Gemfibrozil, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, Digestive System, Hydroxymethylglutaryl-CoA synthase
Abstract

Most of the currently available statins and fibric acid derivatives have been implicated in causing complications either in monotherapy or in combination therapy. Adverse events occur more often with the statins that are metabolized via the CYP enzyme system and its 3A4, 2C9 or 2C19 paths. All compounds interfering with the same cytochrome system may either impair or enhance the elimination of statins. Other factors predisposing to adverse effects are age, female sex, renal insufficiency, electrolyte disturbances, infections and trauma. Complications chiefly concern the hepatic function, skeletal muscles and peripheral nerves. The major adverse effect is myopathy, up to rhabdomyolysis with ensuing acute renal insufficiency. Fibrates bind to peroxisome proliferator-activated nuclear receptors α, with subsequent stimulation of fatty acid oxidation and reduction in the rate of hepatic lipid generation. Fibrates are associated with a number of adverse effects, including liver enzyme elevations, gastrointestinal side effects and rhabdomyolysis. The combination of statins with fibrates may cause serious complications and should be avoided when possible. In order to prevent or minimize adverse clinical outcomes, patients should be closely monitored and informed of the most common symptoms.

Published
2002

9. HMG-CoA Reductase Inhibitors: Is the Endothelium the Main Target?

Author

Giovanni M. Puddu, Paolo Emilio Puddu, and Antonio Muscari

Subjects
medicine.medical_specialty, Statin, Endothelium, Arteriosclerosis, medicine.drug_class, Pharmacology, Nitric Oxide, Nitric oxide, chemistry.chemical_compound, Internal medicine, Antithrombotic, Animals, Humans, Medicine, Pharmacology (medical), Endothelial dysfunction, Endothelin-1, biology, business.industry, Vascular disease, Anticholesteremic Agents, medicine.disease, Endothelin 1, medicine.anatomical_structure, Endocrinology, chemistry, HMG-CoA reductase, biology.protein, Endothelium, Vascular, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business
Abstract

Endothelial dysfunction is an early event in atherosclerosis and could be considered a response to the injury induced by major risk factors. There is evidence that endothelial dysfunction is intimately involved in the onset and the progression of cardiovascular disease through abnormalities in the production, release or degradation of endothelium-derived factors, mainly nitric oxide and endothelin 1. Several reports have shown that drugs of the statin class could have multiple beneficial effects related to endothelium-mediated vasoactive, antithrombotic, antiproliferative and anti-inflammatory actions. Thus, the question arises of whether endothelial cells are the main target of statin therapy, in the setting of both hypercholesterolemia and normocholesterolemia. Experimental and clinical studies are reported that could support this hypothesis.

Published
2001

10. Complement Components and Fibrinogen: Correlations and Association with Previous Myocardial Infarction

Author

Roberto Conte, Antonio Muscari, Paolo Emilio Puddu, Bozzoli C, Massarelli G, Rita Miniero, Gualtiero Palareti, Tiziana D’Atena, Giovanni M. Puddu, Vanda Toscano, Augusto Mazzuca, and Cristina Legnani

Subjects
Adult, Male, medicine.medical_specialty, Antithrombin III, Myocardial Infarction, Radioimmunoassay, Blood Pressure, Fibrinogen, Tissue plasminogen activator, Protein S, Risk Factors, Internal medicine, medicine, Coagulopathy, Humans, Pharmacology (medical), Myocardial infarction, biology, business.industry, Confounding Factors, Epidemiologic, Complement System Proteins, Middle Aged, medicine.disease, Lipids, Complement system, Cerebrovascular Disorders, Cardiovascular Diseases, Tissue Plasminogen Activator, Multivariate Analysis, Immunology, biology.protein, Cardiology, Vitronectin, Cardiology and Cardiovascular Medicine, business, Protein C, medicine.drug
Abstract

Serum complement levels have been found to be predictive of myocardial infarction up to 4 years before the acute event. To assess whether they are a marker of a hypercoagulable state, the serum or plasma levels of C3, C4, C3a, C4a, C1 inactivator, antithrombin III, protein S, protein C, fibrinogen and tissue plasminogen activator were measured in 31 patients with previous myocardial infarction and 33 controls (all males, 40-60 years old). C3, C4 and fibrinogen (which share the common characteristic of being acute phase proteins) were correlated and were associated with previous myocardial infarction, although this association persisted only for C4 in multivariate analysis. None of the coagulative variables directly involved in the complement system differed significantly in the two groups.

Published
1995

11. Contents Vol. 83, 1993

Author

Peiliang Kuan, Janice Bellelsle, Martin J. Thoolen, Gisbert Kober, Charles His, Paolo Scarani, Jian-Ming Li, Lorena Sampieri, Klaus Reynen, Claudius Hansen, Yasushi Asakura, Michiyo Hosokawa, Russell F. Stahl, S.C. Ho, Leo Finci, Hakan Karpuz, Alberto Righetti, Hitoshi Yokozuka, Y.K. Yuen, Joerg-Patrick Stübgen, William Lorelli, Takashi Nishiue, Mark Knox, Renzi C, Toshiji Iwasaka, Juey-Jen Hwang, Wolfram Burger, A. Pacini, A. Viti, Emad Nukta, Antonio Muscari, Tetsuro Sugiura, Rolf Gansser, Toshihisa Anzai, Alberto Zanchetti, N. Ramachandran, Tsutomu Sumimoto, Mitsuo Inada, Mark S. Forsythe, Akira Murayama, Nicolino Molinaro, Kurt Bachmann, Nobuyuki Takahashi, Thomas J. Vander Salm, M. Billi, Giovanni M. Puddu, Wen-Pin Lien, Yutaka Morita, Sharon Jackson, Ghi-Ren Hung, Mauro Borzi, Toshiharu Ishii, Shaker A. Mousa, A. Sham, Paolo Emilio Puddu, Laura Lonati, J.L. Masarei, E. Maioli, Arthur J. Barsky, Cannata D, J. Woo, Monica Bocciolone, Jeremy N. Ruskin, Gastone Leonetti, Marc Carlier, Fragola Pv, Paul D. Cleary, Holger Allroggen, William De Grado, Cesare Cuspidi, Jan Manolas, Bernhard Kunkel, Lea Boselli, Michael V. Smith, Noritaka Tarumi, Jeff M. Bozarth, S.G. Chan, Thomas M. Reilly, Jin-Jer Chen, Carlotta Rovinetti, Giacomino Vallar, Bozzoli C, Claire Cronin, Bernhard Meier, Yoshiro Nakamura, and Jasper Brener

Subjects
Traditional medicine, business.industry, Medicine, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business
Published
1993

12. Increased Serum IgA Levels in Subjects with Previous Myocardial Infarction or Other Major Ischemic Events

Author

Paolo Scarani, Paolo Emilio Puddu, Nicolino Molinaro, Giacomino Vallar, Carlotta Rovinetti, Bozzoli C, Renzi C, Antonio Muscari, and Giovanni M. Puddu

Subjects
Male, medicine.medical_specialty, Immunoglobulin levels, Arteriosclerosis, Myocardial Infarction, Myocardial Ischemia, Immunoglobulin E, Gastroenterology, Angina, Immune system, Increased serum IgA, Internal medicine, medicine, Humans, Pharmacology (medical), Myocardial infarction, Aged, Aged, 80 and over, biology, business.industry, Middle Aged, medicine.disease, Immunoglobulin A, Immunoglobulin M, Immunoglobulin G, Cardiology, biology.protein, Female, Antibody, Cardiology and Cardiovascular Medicine, business, Biomarkers
Abstract

To ascertain whether the increase in serum IgA, which has been found to be associated with the presence of severe atherosclerotic disease, precedes or follows the occurrence of major ischemic events (MIE), we studied the serum levels of IgA as well as IgG and IgM in 145 subjects with acute or previous ischemic events and 34 controls. The subjects with previous myocardial infarction had higher IgA levels with respect to the controls, the patients with angina pectoris and those with acute myocardial infarction, while no significant differences concerning IgG and IgM were found. In the subjects with previous extracoronary events, immunoglobulin levels tended to be even higher. Overall, 30% of the subjects with previous MIE and only 3% of the controls had IgA levels over 4.5 g/l (p = 0.0018). This study indicates that total serum IgA is a marker of previous major ischemic events (protracted immune response to denatured proteins?), rather than a factor predisposing to atherosclerosis development.

Published
1993

14. HMG-CoA Reductase Inhibitors: Is the Endothelium the Main Target?

Author

Muscari, Antonio, Puddu, Paolo, and Puddu, Giovanni M.

Subjects
*HYDROXYMETHYLGLUTARYL coenzyme A reductases, *STATINS (Cardiovascular agents), *NITRIC oxide, *ENDOTHELINS, *ATHEROSCLEROSIS
Abstract

Endothelial dysfunction is an early event in atherosclerosis and could be considered a response to the injury induced by major risk factors. There is evidence that endothelial dysfunction is intimately involved in the onset and the progression of cardiovascular disease through abnormalities in the production, release or degradation of endothelium-derived factors, mainly nitric oxide and endothelin 1. Several reports have shown that drugs of the statin class could have multiple beneficial effects related to endothelium-mediated vasoactive, antithrombotic, antiproliferative and anti-inflammatory actions. Thus, the question arises of whether endothelial cells are the main target of statin therapy, in the setting of both hypercholesterolemia and normocholesterolemia. Experimental and clinical studies are reported that could support this hypothesis.Copyright © 2001 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

15. Subject Index, Vol. 83, 1993

Author

Yoshiro Nakamura, Hakan Karpuz, Alberto Righetti, Tetsuro Sugiura, Toshiji Iwasaka, Hitoshi Yokozuka, Leo Finci, Takashi Nishiue, Paolo Emilio Puddu, Renzi C, Toshiharu Ishii, Toshihisa Anzai, Y.K. Yuen, William Lorelli, Monica Bocciolone, Cannata D, A. Viti, Laura Lonati, Nobuyuki Takahashi, Arthur J. Barsky, M. Billi, Marc Carlier, Rolf Gansser, Russell F. Stahl, Yutaka Morita, Antonio Muscari, Martin J. Thoolen, Paul D. Cleary, Mitsuo Inada, N. Ramachandran, Sharon Jackson, Giacomino Vallar, Peiliang Kuan, Shaker A. Mousa, Noritaka Tarumi, Jeremy N. Ruskin, Michael V. Smith, Emad Nukta, Gisbert Kober, Mauro Borzi, Jian-Ming Li, Lorena Sampieri, Mark Knox, Tsutomu Sumimoto, Ghi-Ren Hung, Bernhard Kunkel, Janice Bellelsle, E. Maioli, Jasper Brener, A. Pacini, Thomas M. Reilly, Claudius Hansen, J. Woo, Yasushi Asakura, Bernhard Meier, Wen-Pin Lien, Joerg-Patrick Stübgen, Charles His, Paolo Scarani, Fragola Pv, Giovanni M. Puddu, Jeff M. Bozarth, William De Grado, Cesare Cuspidi, Michiyo Hosokawa, Jan Manolas, Holger Allroggen, Klaus Reynen, Thomas J. Vander Salm, S.G. Chan, Bozzoli C, J.L. Masarei, Jin-Jer Chen, Gastone Leonetti, Kurt Bachmann, Akira Murayama, Juey-Jen Hwang, Wolfram Burger, Mark S. Forsythe, Nicolino Molinaro, Alberto Zanchetti, Claire Cronin, A. Sham, S.C. Ho, Lea Boselli, and Carlotta Rovinetti

Subjects
Index (economics), business.industry, Statistics, Medicine, Pharmacology (medical), Subject (documents), Cardiology and Cardiovascular Medicine, business
Published
1993

16. Complement Components and Fibrinogen: Correlations and Association with Previous Myocardial Infarction

Author

Muscari, Antonio, primary, Bozzoli, Claudio, additional, Massarelli, Giorgio, additional, Puddu, Giovanni M., additional, Palareti, Gualtiero, additional, Legnani, Cristina, additional, D’Atena, Tiziana, additional, Mazzuca, Augusto, additional, Miniero, Rita, additional, Toscano, Vanda, additional, Conte, Roberto, additional, and Puddu, Paolo, additional

Published
1995
Full Text
View/download PDF

18. Discussion des Communications XV-XVII

Author

Henri Denolin, C. Dubost, L. Scébat, C. Ferrero, Max Holzmann, J. Lenègre, P. Decker, Ettore Rossi, V. Puddu, M. Mathivat, J. Facquet, A. Grilli, F. D’allaines, P. Waser, A. Weber, J. Piequet, M. Durand, C. Maier, C. Callebaut, T. Tcheng, W. Hunzinger, J. Lequime, P.Y. Hatt, E. Rothlin, E. Mannheimer, P.W. Dughosal, P.H. Rossier, A. Cerletti, P.W. Duchosal, I. Mahaim, J.P. Doret, J. Grosgurin, F. Bamatter, E. Landau, M. Volkmann, and John Mcmichael

Subjects
business.industry, Medicine, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business, Humanities
Published
1950

19. Contents, Vol. 52, 1968

Author

M. Samanek, W. Raab, A. Van Bogaert, W. Chrzanowski, Adriana Mussafia, S. Bellet, F. Palecek, T. Noskowicz, V. Puddu, and D.M. Aviado

Subjects
Traditional medicine, business.industry, Medicine, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business
Published
1968

20. On the Significance of the Negative T Wave Pattern in Lead AVL in Horizontal Heart

Author

Adriana Mussafia and V. Puddu

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Heart Diseases, medicine.diagnostic_test, business.industry, Heart position, Middle Aged, Diagnosis, Differential, Electrocardiography, Negative t wave, Internal medicine, T wave, medicine, Cardiology, Humans, Female, Pharmacology (medical), Cardiology and Cardiovascular Medicine, Lead (electronics), business, Aged
Published
1968

22. Habitual Physical Activity and Myocardial Infarction

Author

Alessandro Menotti, F. Fidanza, V. Puddu, and M. Monti

Subjects
Adult, Male, Longitudinal study, medicine.medical_specialty, business.industry, Physical Exertion, Myocardial Infarction, Physical activity, Middle Aged, medicine.disease, Internal medicine, medicine, Cardiology, Humans, Pharmacology (medical), Myocardial infarction, Occupations, Cardiology and Cardiovascular Medicine, business
Published
1969

24. Papers published by Gustav Nylin

Author

Alberico Collicelli, Pentti I. Halonen, Karlman Wasserman, Brita Stackelberg, Max Taeschler, John H. Lawrence, U.S. von Euler, F. Joly, J. Dankmeijer, G. Hevesy, Miss R.M. Collister, John Lind, L. Condorelli, Vittorio Puddu, E. Nusser, Milton Plotz, Karl Erik Grewin, G.R. de Vleeschhouwer, J. Winberg, Jeremiah Stamler, E. Arjona, Erik Warburg, Bertil von Ahn, Luigi Comberiati, A. Kahlstorf, F. Van Dooren, Robalo Cordeiro, P. Courtoy, John E. Hewitt, Samuel A. Levine, Paul J. Elmlinger, J.M. Fonseca, J. Kenis, A. Nunes, E. Coelho, R. Spritzler, J. Lequime, Paul Uhlenbruck, Johan Karnell, Sven Åkesson, E. Mannheimer, C. Heymans, Robert B. Green, Miss C. Bruins, N. Boyadjian, F.J. Eckervogt, Paul D. White, H.C. Bergman, Carl Wegelius, Sven Rohlin, F. Heinzel, A. Cerletti, Francis M. Rackemann, B.A. Houssay, Gunnar Biörck, Bror Broden, G. Fulton, J. Zissler, Alberto C. Taquini, Richard R. Evans, Robert L. Levy, Fredrik Sundelin, E. Rothlin, Werner Schmitz, Charles Laubry, H. Denolin, A. Weber, Erik Ask-Upmark, F. Wahlgren, A.N. Kuusisto, Frank T. Pierce, R.J. Bing, J.M. Alés, E. Braun-Menendez, C. Jiménez-Diaz, K. Matthes, Augusto Mascarenhas, Crighton Bramwell, Hardin B. Jones, Richard Bauersfeld, K. Mechelke, Hjalmar Wijnbladh, P. Soulié, Gösta von Reis, C.L.C. Van Nieuwenhuizen, Camille Lian, Arrigo Poppi, Harald Eliasch, E. Wollheim, F. Barros, E. Bengtsson, Thomas L. Hayes, J. Lenègre, P. Koskelo, Donald E. Love, M. Eifert, Marcello Martinelli, J.-L. Rivier, M. Prinzmetal, Helen B. Taussig, Gunnar Jonsson, K.W. Schneider, Asger Pedersen, H.A. Snellen, John W. Gofman, Lars Werkö, G. Folli, Bertram V.A. Low-Beer, I. Mahaim, Geoffrey Reynolds, Irving S. Wright, Werner Weissel, Åke Thorson, Maurice Campbell, J. Di Matteo, H.S. Mayerson, E. Corday, H.E.J. Houssay, Thérèse Brosse, Louis N. Katz, Joao Porto, and Jairo Ramos

Subjects
business.industry, Medicine, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business, Classics
Published
1952

26. Dedication Gustav Nylin

Author

A. Nunes, E. Coelho, G. Fulton, Louis N. Katz, Joao Porto, F. Van Dooren, E. Arjona, Marcello Martinelli, C.L.C. Van Nieuwenhuizen, C. Jiménez-Diaz, Bror Brodén, E. Braun-Menendez, P. Soulié, Gunnar Biörck, Harald Eliasch, Maurice Campbell, J.M. Alés, J.-L. Rivier, F. Barros, H.C. Bergman, Francis M. Rackemann, Paul D. White, Åke Thorson, Camille Lian, K.W. Schneider, Richard R. Evans, H. Denolin, H.E.J. Houssay, J. Lequime, Thérèse Brosse, Miss C. Bruins, A.N. Kuusisto, R.J. Bing, John H. Lawrence, M. Eifert, Fredrik Sundelin, Augusto Mascarenhas, Crighton Bramwell, F. Joly, Luigi Comberiati, Karl Erik Grewin, Pentti I. Halonen, G. Hevesy, A. Weber, I. Mahaim, P. Courtoy, G.R. de Vleeschhouwer, John E. Hewitt, E. Nusser, Paul Uhlenbruck, Erik Warburg, A. Cerletti, E. Corday, J. Winberg, Miss R.M. Collister, Gunnar Jönsson, Hjalmar Wijnbladh, Thomas L. Hayes, Donald E. Love, Sven Åkesson, E. Mannheimer, Sven Rohlin, H.S. Mayerson, J.M. Fonseca, B.A. Houssay, F.J. Eckervogt, J. Zissler, Werner Schmitz, Robert B. Green, H.A. Snellen, Alberico Collicelli, Erik Ask-Upmark, J. Kenis, C. Heymans, Vittorio Puddu, F. Heinzel, R. Spritzler, John W. Gofman, Robert L. Levy, Lars Werkö, G. Folli, N. Boyadjian, Geoffrey Reynolds, Bertram V.A. Low-Beer, Johan Karnell, Gösta von Reis, Richard Bauersfeld, K. Mechelke, F. Wahlgren, Samuel A. Levine, J. Dankmeijer, Jairo Ramos, E. Bengtsson, U.S. von Euler, Milton Plotz, M. Prinzmetal, Helen B. Taussig, E. Wollheim, Charles Laubry, Brita Stackelberg, Jeremiah Stamler, Bertil von Ahn, Carl Wegelius, Alberto C. Taquini, Asger Pedersen, Robalo Cordeiro, A. Kahlstorf, Frank T. Pierce, Paul J. Elmlinger, Karlman Wasserman, Max Taeschler, John Lind, L. Condorelli, Arrigo Poppi, J. Lenègre, Irving S. Wright, Werner Weissel, P. Koskelo, J. Di Matteo, E. Rothlin, K. Matthes, and Hardin B. Jones

Subjects
business.industry, Medicine, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business, Classics
Published
1952

27. Introduction du President

Author

M. Durand, I. Mahaim, J.P. Doret, W. Hunzinger, Henri Denolin, M. Mathivat, C. Maier, Max Holzmann, P.W. Dughosal, P. Decker, J. Grosgurin, V. Puddu, J. Piequet, A. Grilli, E. Rothlin, F. Bamatter, C. Dubost, C. Ferrero, T. Tcheng, Ettore Rossi, J. Facquet, J. Lequime, F. D’allaines, L. Scébat, A. Weber, C. Callebaut, P.Y. Hatt, J. Lenègre, E. Landau, P.H. Rossier, M. Volkmann, P.W. Duchosal, E. Mannheimer, A. Cerletti, John Mcmichael, and P. Waser

Subjects
medicine.medical_specialty, Pediatrics, business.industry, Family medicine, medicine, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business
Published
1950

36. Société Suisse de Cardiologie. Schweizerische Kardiologische Gesellschaft

Author

I. Mahaim, J. Lequime, A. Weber, L. Scébat, P. Decker, J.P. Doret, Ettore Rossi, M. Mathivat, C. Maier, J. Piequet, V. Puddu, E. Mannheimer, T. Tcheng, A. Grilli, P.H. Rossier, Max Holzmann, E. Landau, A. Cerletti, John Mcmichael, M. Durand, M. Volkmann, J. Facquet, P.W. Dughosal, W. Hunzinger, P.Y. Hatt, Henri Denolin, E. Rothlin, J. Grosgurin, F. Bamatter, C. Callebaut, J. Lenègre, C. Dubost, P.W. Duchosal, C. Ferrero, F. D’allaines, and P. Waser

Subjects
business.industry, Medicine, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business, Humanities
Published
1950

37. Book Review – Buchbesprechung – Livres nouveaux

Author

F. Palecek, W. Chrzanowski, M. Samanek, W. Raab, V. Puddu, T. Noskowicz, A. van Bogaert, D.M. Aviado, Adriana Mussafia, and S. Bellet

Subjects
business.industry, Medicine, Art history, Pharmacology (medical), Cardiology and Cardiovascular Medicine, business
Published
1968

Catalog

Books, media, physical & digital resources
See catalog results